Cargando…

Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia

This study aimed to observe the safety and clinical efficacy of early application of ruxolitinib to prevent acute graft-versus-host disease (aGVHD) after alternative donor transplantation in acute leukemia. There were 57 patients undergoing allo-HSCT at the Affiliated Cancer Hospital of Zhengzhou Un...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Binglei, Chen, Lingyun, Zhou, Jian, Zu, Yingling, Gui, Ruirui, Li, Zhen, Wang, Juan, Yu, Fengkuan, Zhang, Yanli, Zhao, Huifang, Ji, Zhenyu, Song, Yongping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055912/
https://www.ncbi.nlm.nih.gov/pubmed/33875780
http://dx.doi.org/10.1038/s41598-021-88080-3
_version_ 1783680539443593216
author Zhang, Binglei
Chen, Lingyun
Zhou, Jian
Zu, Yingling
Gui, Ruirui
Li, Zhen
Wang, Juan
Yu, Fengkuan
Zhang, Yanli
Zhao, Huifang
Ji, Zhenyu
Song, Yongping
author_facet Zhang, Binglei
Chen, Lingyun
Zhou, Jian
Zu, Yingling
Gui, Ruirui
Li, Zhen
Wang, Juan
Yu, Fengkuan
Zhang, Yanli
Zhao, Huifang
Ji, Zhenyu
Song, Yongping
author_sort Zhang, Binglei
collection PubMed
description This study aimed to observe the safety and clinical efficacy of early application of ruxolitinib to prevent acute graft-versus-host disease (aGVHD) after alternative donor transplantation in acute leukemia. There were 57 patients undergoing allo-HSCT at the Affiliated Cancer Hospital of Zhengzhou University from July 2017 to October 2019. They were divided into control(16 patients) and ruxolitinib (41 patients) groups. For aGVHD prophylaxis, the control group received post-transplantation cyclophosphamide, antithymocyte globulin-Fresenius, cyclosporine A, and mycophenolate mofetil, while in the ruxolitinib group, ruxolitinib 5 mg/d in adults or 0.07–0.1 mg/(kg d) in children was administered from the day of neutrophil engraftment to 100 days post-transplantation based on control group. We found 55 patients had successful reconstitution of hematopoiesis; No significant difference was found in cGVHD, hemorrhagic cystitis, pulmonary infection, intestinal infection, Epstein-Barr virus infection, cytomegalovirus infection, relapse, death, and nonrelapse mortality. The incidences of aGVHD (50 vs. 22%, P = 0.046) and grade II–IV aGVHD (42.9 vs. 12.2%, P = 0.013) were significantly higher in the control group than in the ruxolitinib group. No significant differences were observed in overall survival (P = 0.514), disease-free survival (P = 0.691), and cumulative platelet transfusion within 100 days post-transplantation between two groups. This suggests early application of ruxolitinib can reduce the incidence and severity of aGVHD and patients are well tolerated.
format Online
Article
Text
id pubmed-8055912
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-80559122021-04-22 Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia Zhang, Binglei Chen, Lingyun Zhou, Jian Zu, Yingling Gui, Ruirui Li, Zhen Wang, Juan Yu, Fengkuan Zhang, Yanli Zhao, Huifang Ji, Zhenyu Song, Yongping Sci Rep Article This study aimed to observe the safety and clinical efficacy of early application of ruxolitinib to prevent acute graft-versus-host disease (aGVHD) after alternative donor transplantation in acute leukemia. There were 57 patients undergoing allo-HSCT at the Affiliated Cancer Hospital of Zhengzhou University from July 2017 to October 2019. They were divided into control(16 patients) and ruxolitinib (41 patients) groups. For aGVHD prophylaxis, the control group received post-transplantation cyclophosphamide, antithymocyte globulin-Fresenius, cyclosporine A, and mycophenolate mofetil, while in the ruxolitinib group, ruxolitinib 5 mg/d in adults or 0.07–0.1 mg/(kg d) in children was administered from the day of neutrophil engraftment to 100 days post-transplantation based on control group. We found 55 patients had successful reconstitution of hematopoiesis; No significant difference was found in cGVHD, hemorrhagic cystitis, pulmonary infection, intestinal infection, Epstein-Barr virus infection, cytomegalovirus infection, relapse, death, and nonrelapse mortality. The incidences of aGVHD (50 vs. 22%, P = 0.046) and grade II–IV aGVHD (42.9 vs. 12.2%, P = 0.013) were significantly higher in the control group than in the ruxolitinib group. No significant differences were observed in overall survival (P = 0.514), disease-free survival (P = 0.691), and cumulative platelet transfusion within 100 days post-transplantation between two groups. This suggests early application of ruxolitinib can reduce the incidence and severity of aGVHD and patients are well tolerated. Nature Publishing Group UK 2021-04-19 /pmc/articles/PMC8055912/ /pubmed/33875780 http://dx.doi.org/10.1038/s41598-021-88080-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Zhang, Binglei
Chen, Lingyun
Zhou, Jian
Zu, Yingling
Gui, Ruirui
Li, Zhen
Wang, Juan
Yu, Fengkuan
Zhang, Yanli
Zhao, Huifang
Ji, Zhenyu
Song, Yongping
Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia
title Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia
title_full Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia
title_fullStr Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia
title_full_unstemmed Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia
title_short Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia
title_sort ruxolitinib early administration reduces acute gvhd after alternative donor hematopoietic stem cell transplantation in acute leukemia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055912/
https://www.ncbi.nlm.nih.gov/pubmed/33875780
http://dx.doi.org/10.1038/s41598-021-88080-3
work_keys_str_mv AT zhangbinglei ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia
AT chenlingyun ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia
AT zhoujian ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia
AT zuyingling ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia
AT guiruirui ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia
AT lizhen ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia
AT wangjuan ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia
AT yufengkuan ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia
AT zhangyanli ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia
AT zhaohuifang ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia
AT jizhenyu ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia
AT songyongping ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia